drugset / Trial / NCT00482508
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will assess the safety and tolerability of long-term treatment with omalizumab plus current asthma therapy in patients who participated in and successfully completed the treatment period of study CIGE025IA04E1. Patients who participated in CIGE025IA04E1 were perceived by both the patient and the investigator to have benefited from receiving treatment with omalizumab plus current asthma therapy according to best medical practice
Timeline
- Start
- 2003-05
- Primary completion
- 2005-10
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | — | — |